BidaskClub lowered shares of Natus Medical Incorporated (NASDAQ:BABY) from a sell rating to a strong sell rating in a research note released on Thursday morning.

Several other research firms have also recently weighed in on BABY. Zacks Investment Research raised Natus Medical from a sell rating to a hold rating in a report on Tuesday, June 27th. Benchmark Co. reaffirmed a buy rating and issued a $48.00 price target (down previously from $55.00) on shares of Natus Medical in a report on Monday, May 1st. Finally, TheStreet cut Natus Medical from a b rating to a c+ rating in a report on Thursday, April 27th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. Natus Medical currently has an average rating of Hold and a consensus price target of $45.00.

Shares of Natus Medical (BABY) opened at 32.45 on Thursday. The stock has a 50 day moving average of $35.42 and a 200 day moving average of $36.37. Natus Medical has a 12-month low of $31.65 and a 12-month high of $44.39. The company has a market cap of $1.06 billion, a price-to-earnings ratio of 56.24 and a beta of 0.93.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm had revenue of $122.20 million for the quarter, compared to analysts’ expectations of $121.99 million. During the same quarter last year, the firm posted $0.39 EPS. The company’s revenue was up 27.3% compared to the same quarter last year. On average, equities analysts expect that Natus Medical will post $1.70 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://theolympiareport.com/2017/08/28/natus-medical-incorporated-baby-stock-rating-lowered-by-bidaskclub.html.

In related news, Director William M. Moore sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $34.10, for a total transaction of $102,300.00. Following the transaction, the director now directly owns 30,410 shares in the company, valued at approximately $1,036,981. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider James B. Hawkins purchased 6,000 shares of Natus Medical stock in a transaction that occurred on Wednesday, May 31st. The shares were bought at an average price of $33.81 per share, for a total transaction of $202,860.00. The disclosure for this purchase can be found here. 5.50% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of BABY. BlackRock Inc. raised its position in Natus Medical by 137,510.8% in the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock valued at $161,874,000 after buying an additional 4,121,198 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in shares of Natus Medical during the first quarter worth $110,000. Kennedy Capital Management Inc. raised its stake in shares of Natus Medical by 12.9% in the first quarter. Kennedy Capital Management Inc. now owns 316,253 shares of the medical equipment provider’s stock worth $12,413,000 after buying an additional 36,151 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Natus Medical by 1.7% in the first quarter. State of Alaska Department of Revenue now owns 3,630 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 60 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Natus Medical by 4.8% in the first quarter. Vanguard Group Inc. now owns 2,274,870 shares of the medical equipment provider’s stock worth $89,289,000 after buying an additional 105,008 shares in the last quarter. Institutional investors and hedge funds own 92.65% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.